Rheumatoid Arthritis News

    Skip to content
    • Home
    • Treatments
      • Tofacitinib (Xeljanz)
    • Experimental Treatments
      • Piclidenoson
      • Kevzara (Sarilumab)
      • Baricitinib (Olumiant)
    • About Us
    • Contact Us
    •
      June 12, 2017August 24, 2022

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and Drug ... Read more
    • June 7, 2017June 7, 2017

      Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according ... Read more
    • June 5, 2017June 5, 2017

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), ... Read more
    • June 2, 2017June 2, 2017

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), ‎Remicade (infliximab), ‎Simponi (golimumab), or ‎Cimzia (certolizumab), are less cost-effective ... Read more
    • May 23, 2017May 23, 2017

      Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs

      Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis ... Read more
    MicroRNA May Offer Way to Control T-cells in RA and Other Autoimmune Diseases
    August 8, 2016August 8, 2016

    MicroRNA May Offer Way to Control T-cells in RA and Other Autoimmune Diseases

    News
    An international collaboration involving researchers at The Scripps Research Institute (TSRI) unveiled the role a small molecule called microRNA-155 (miR-155) plays in our immune system, a finding that could help scientists develop novel therapies ... Read more
    Generic Biologic Drugs Appear Comparable to Brand-name Counterparts, According to Review
    August 5, 2016August 5, 2016

    Generic Biologic Drugs Appear Comparable to Brand-name Counterparts, According to Review

    News
    A new Johns Hopkins Bloomberg School of Public Health systematic review indicates that generic forms of a biologic drug for the treatment of rheumatoid arthritis and other autoimmune diseases seem ... Read more
    Novel Rheumatoid Arthritis Treatment Developed by BIOCAD
    August 3, 2016August 3, 2016

    Novel Rheumatoid Arthritis Treatment Developed by BIOCAD

    News
    BIOCAD has advanced a novel medicine for autoimmune diseases that include rheumatoid arthritis (RA), and psoriatic arthritis (PsA). The company’s new drug candidate BCD-121 is forecast to increase the efficacy of RA treatment up to 20% compared with ... Read more
    Navidea’s Phase 1 Trial of Lymphoseek for Rheumatoid Arthritis Gets IRB Approval
    August 1, 2016August 1, 2016

    Navidea’s Phase 1 Trial of Lymphoseek for Rheumatoid Arthritis Gets IRB Approval

    News
    The University of California, San Francisco School of Medicine has granted Institutional Review Board (IRB) approval to Navidea Biopharmaceuticals to conduct a Phase 1 clinical trial evaluating Lymphoseek (technetium Tc 99m tilmanocept) injection to ... Read more
    In Rheumatoid Arthritis Patients, Immunotherapy Appears to Reduce Cardiovascular Risk
    July 29, 2016July 29, 2016

    In Rheumatoid Arthritis Patients, Immunotherapy Appears to Reduce Cardiovascular Risk

    News
    Patients with rheumatoid arthritis (RA) treated with an immunotherapy of low-dose combination of two anticytokines have a reduced disease activity and a lower risk for cardiac events, according to researchers. These findings ... Read more
    Gut Bacteria Might Predict, Prevent Rheumatoid Arthritis Start, Severity
    July 27, 2016July 27, 2016

    Gut Bacteria Might Predict, Prevent Rheumatoid Arthritis Start, Severity

    News
    New studies suggest that bacteria in the gut may predict susceptibility to rheumatoid arthritis (RA), be used by physicians to prevent disease onset, and that altering the gut microbiome composition can improve RA ... Read more
    FDA-approved Orencia ClickJect for Rheumatoid Arthritis Launched by BMS
    July 25, 2016July 25, 2016

    FDA-approved Orencia ClickJect for Rheumatoid Arthritis Launched by BMS

    News
    Bristol-Myers Squibb has launched its U.S. FDA-approved Orencia ClickJect Autoinjector for adults with moderate to severe rheumatoid arthritis (RA). Orencia (abatacept) is a modified antibody drug that interferes with the immune activity of T-cells and can treat the symptoms of rheumatoid ... Read more
    App Enables iPhone to Monitor Rheumatoid Arthritis Study Participants
    July 22, 2016July 22, 2016

    App Enables iPhone to Monitor Rheumatoid Arthritis Study Participants

    News
    Global pharmaceutical and healthcare products company GlaxoSmithKline (GSK) has launched the “Patient Rheumatoid Arthritis Data from the Real World” (PARADE) clinical study, using Apple iPhones to monitor activity and vital ... Read more
    Rheumatoid Arthritis Patients May See Improvement by Vagus Nerve Stimulation, Study Finds
    July 20, 2016July 20, 2016

    Rheumatoid Arthritis Patients May See Improvement by Vagus Nerve Stimulation, Study Finds

    News
    Stimulating the vagus nerve with electrical signals significantly improves disease severity of rheumatoid arthritis (RA), according to a new study, “Vagus nerve stimulation inhibits cytokine production and attenuates disease severity ... Read more
    FDA Arthritis Advisory Committee Hears Perspectives on Biosimilar GP2015
    July 15, 2016July 18, 2016

    FDA Arthritis Advisory Committee Hears Perspectives on Biosimilar GP2015

    News
    The U.S. Food and Drug Administration (FDA) held Arthritis Advisory Committee Meetings, July 11-12 in Maryland, and discussed Biologics License Applications (BLA) approvals, including a submission for GP2015, Sandoz‘s proposed biosimilar product to Amgen’s drug ... Read more

    Posts navigation

    Older posts
    Newer posts

    Never miss another RA update.

    * indicates required
    Bionews, Inc.
    3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363

    Recent Posts

    • Diplomat selling Kevzara

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      June 12, 2017

    • Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      June 7, 2017

    • Truxima, a biosimilar of rituximab

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      June 5, 2017

    • triple therapy

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      June 2, 2017

    • About Us
    • Contact Us
    • Terms of Service
    • Privacy Policy

    Disclaimer:

    Rheumatoid Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
    Copyright © 2013-2025 All rights reserved.